Oncologia Personalizzata

XEPTAGEN SpA è attivamente impegnata nella scoperta e nella validazione di nuovi marcatori per migliorare la gestione clinica del paziente oncologico sviluppando trattamenti terapeutici personalizzati.

Products Highlight

Latest Product Literature

SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy. Obes Facts. 12:291–306. 2019.

MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma.. J Clin Med. 8(2). 2019.

Squamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity.. Cancer Sci.. 110(5):1552-1563. 2019.

Actual evidences and future perspectives about the role of iXip® in the diagnosis of prostate cancer: a narrative review.. Minerva Urol Nefrol. . 2019.

Clinical significances and diagnostic utilities of both miR-215 and squamous cell carcinoma antigen-IgM versus alpha-fetoprotein in Egyptian patients with hepatitis C virus-induced hepatocellular carcinoma.. Clin Exp Gastroenterol.. 12:51-66. 2019.

Diagnostic accuracy of SCCA and SCCA-IgM for hepatocellular carcinoma: A meta-analysis. Liver Int.. 38:1820–1831. 2018.

Comunicati stampa


Tweets by Xeptagen